Sydney Jennings

FDA approved Mucinex 12HR Cold & Fever Multi-Symptom, an OTC product combining guaifenesin, dextromethorphan, and naproxen sodium.

FDA approval of centanafadine could expand ADHD treatment for patients aged 6 years or older, but labeling and pivotal data remain unavailable.

A McGill University–led team developed a prediction model integrating pregnancy-related factors to identify cardiovascular disease risk in women aged 15 to 45.

Recent FDA actions include approvals and clearances in lipid management, CRC screening, contraception, vaginitis testing, and Alzheimer psychosis.

FDA cleared Roche’s cobas BV/CV assay to detect bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

Topline TRIUMPH-2 and TRIUMPH-3 results showed retatrutide reduced weight by up to 20.8% in adults with type 2 diabetes and 22.6% in adults with CVD.

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

A peer-reviewed study found FDA-cleared IGeneX immunoblot tests detected 58.3% of early Lyme cases vs 30.0% with standard two-tier testing.

A new study links semaglutide and tirzepatide to fewer alcohol-related hospitalizations in adults with AUD and diabetes or obesity.

A cross-sectional study linked compulsive smartphone use and limited offline social activity to depressive symptoms in adults aged 60 years or older.

ACOG updated HIV screening and prevention guidance, recommending opt-out lifetime HIV testing and stronger PrEP counseling and prescribing.

A new analysis estimates the 2026 dyslipidemia guideline expands primary prevention statin eligibility to 87.5 million US adults.

FDA accepted Shionogi’s sNDA for cefiderocol for pediatric HABP/VABP and complicated UTI caused by certain Gram-negative bacteria.

The US FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH.

FDA accepted Axsome’s NDA for AXS-12 for cataplexy in narcolepsy and set a PDUFA target action date of May 1, 2027.

Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.

The 2026 global status report on cancer projects nearly 35 million new cases annually by 2050 and underscores urgent action on prevention and care access.

AI-generated portal message drafts often missed clinical context and required physician editing in a Dartmouth analysis.

Phase 2 TRAPEDS-1 trial data show tralokinumab produced consistent pharmacokinetics and tolerability in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.

FDA approval makes Differin Epiduo Acne Gel available OTC for patients aged 12 years or older with acne.

Clinicians discuss DKA risk, sick day plans, CGM use, and ketone testing in primary care.

Eden Miller, DO, and panelists discuss DKA recognition gaps, ketone testing barriers, and the future of dual glucose-ketone sensing.

The FDA recently approved the first generic baloxavir tablet for influenza treatment and postexposure prophylaxis in patients aged 5 years or older.

CGM prescribing in primary care was associated with lower HbA1c levels, fewer hospitalizations, and fewer ED visits among insulin-treated adults.

A primary care telehealth mindfulness program improved chronic low back pain and pain interference through 12 months in OPTIMUM.

FDA authorized a reduced-risk claim for 20 ZYN nicotine pouches for adults who switch completely from cigarettes.

A 10-week video-based cognitive rehabilitation program improved patient-set goals in adults with long COVID cognitive symptoms.

Recent FDA actions include updates on COVID-19 prophylaxis, ADHD, PTSD neuromodulation, and pediatric psoriasis and psoriatic arthritis care.

FDA approved roflumilast (Zoryve) cream 0.3% for plaque psoriasis in children as young as age 2, expanding the once-daily steroid-free topical indication.